Related Experiment Videos

Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma

T Nakashima1, J M Hudson, G L Clayman

  • 1Department of Head and Neck Surgery, The University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA.

Head & Neck
|July 18, 2000
PubMed
Abstract

Insights

Antisense VEGF transfection significantly reduced vascular endothelial growth factor (VEGF) secretion in head and neck cancer cells. This approach shows potential for suppressing tumor angiogenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis, crucial for tumor growth.
  • Squamous cell carcinoma of the head and neck (SCCHN) is known to secrete VEGF.
  • Understanding VEGF's role in SCCHN is vital for developing targeted therapies.

Purpose of the Study:

  • To investigate the efficacy of antisense VEGF transfection in suppressing angiogenic activity of SCCHN cells.
  • To determine if down-regulating VEGF impacts endothelial cell migration and tumor growth in vivo.

Main Methods:

  • Screening of human SCCHN cell lines for VEGF secretion using ELISA.
  • Transfection of high-VEGF secreting SCCHN cells with an antisense VEGF vector.
  • Assessing endothelial cell migration using conditioned medium from transfected cells and evaluating tumor growth in nude mice.

Main Results:

  • Antisense VEGF transfection led to a 20-fold reduction in VEGF secretion.
  • Conditioned medium from antisense clones reduced endothelial cell migration by 50%.
  • No significant impact on in vivo tumor growth was observed.

Conclusions:

  • Antisense VEGF transfection effectively down-regulates VEGF secretion in SCCHN cells.
  • Targeting VEGF expression presents a promising strategy for inhibiting angiogenesis in head and neck cancers.
  • Further research is needed to explore the in vivo therapeutic potential.

Related Concept Videos